KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Payables (2016 - 2025)

Arbutus Biopharma's Payables history spans 15 years, with the latest figure at $4.7 million for Q3 2025.

  • For Q3 2025, Payables fell 38.32% year-over-year to $4.7 million; the TTM value through Sep 2025 reached $4.7 million, down 38.32%, while the annual FY2024 figure was $7.6 million, 26.36% down from the prior year.
  • Payables for Q3 2025 was $4.7 million at Arbutus Biopharma, up from $4.5 million in the prior quarter.
  • Across five years, Payables topped out at $16.0 million in Q4 2022 and bottomed at $4.5 million in Q2 2025.
  • The 5-year median for Payables is $9.7 million (2023), against an average of $9.3 million.
  • The largest annual shift saw Payables surged 70.07% in 2021 before it plummeted 59.42% in 2025.
  • A 5-year view of Payables shows it stood at $10.8 million in 2021, then soared by 47.9% to $16.0 million in 2022, then plummeted by 35.92% to $10.3 million in 2023, then fell by 26.36% to $7.6 million in 2024, then crashed by 38.48% to $4.7 million in 2025.
  • Per Business Quant, the three most recent readings for ABUS's Payables are $4.7 million (Q3 2025), $4.5 million (Q2 2025), and $12.1 million (Q1 2025).